Comparative Messaging, Learning and Forgetting: Evidence from Pharmaceutical Drug Detailing

2020 ◽  
Author(s):  
Xiaojing Dong ◽  
Ying Xie ◽  
Pradeep K. Chintagunta
Planta Medica ◽  
2008 ◽  
Vol 74 (09) ◽  
Author(s):  
C Delattre ◽  
P Michaud ◽  
JY Berthon ◽  
L Rios
Keyword(s):  

2010 ◽  
Vol 38 (1) ◽  
pp. 74-84 ◽  
Author(s):  
David Orentlicher

Pharmaceutical companies have long relied on direct marketing of their drugs to physicians through one-on-one meetings with sales representatives. This practice of “detailing” is substantial in its costs and its number of participants. Every year, pharmaceutical companies spend billions of dollars on millions of visits to physicians by tens of thousands of sales representatives.Critics have argued that drug detailing results in sub-optimal prescribing decisions by physicians, compromising patient health and driving up spending on medical care. In this view, physicians often are unduly influenced both by marketing presentations that do not accurately reflect evidence from the medical literature and by the gifts that sales representatives deliver in conjunction with their presentations.


2021 ◽  
Author(s):  
Brian T. Pentland ◽  
Youngjin Yoo ◽  
Jan Recker ◽  
Inkyu Kim

We offer a path-centric theory of emerging technology and organizing that addresses a basic question. When does emerging technology lead to transformative change? A path-centric perspective on technology focuses on the patterns of actions afforded by technology in use. We identify performing and patterning as self-reinforcing mechanisms that shape patterns of action in the domain of emerging technology and organizing. We use a dynamic simulation to show that performing and patterning can lead to a wide range of trajectories, from lock-in to transformation, depending on how emerging technology in use influences the pattern of action. When emerging technologies afford new actions that can be flexibly recombined to generate new paths, decisive transformative effects are more likely. By themselves, new affordances are not likely to generate transformation. We illustrate this theory with examples from the practice of pharmaceutical drug discovery. The path-centric perspective offers a new way to think about generativity and the role of affordances in organizing.


Sign in / Sign up

Export Citation Format

Share Document